Journal
EUROPEAN JOURNAL OF CANCER
Volume 47, Issue -, Pages S116-S130Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S0959-8049(11)70155-1
Keywords
-
Categories
Ask authors/readers for more resources
Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular alterations in tumours offer the promise of significantly improved treatment. So far, the most promising targeted agents are angiogenesis inhibitors and PARP inhibitors. Here, we review the various targeted therapeutic approaches under clinical investigation in phase I and II trials of ovarian cancer and the challenges facing their future success in the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available